The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old.1 Two other RSV vaccines have received FDA approval: Abrysvo, a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants,1 and mResvia, an mRNA vaccine recently licensed for use in...
- Iloprost (Aurlumyn) for Frostbite
- Iloperidone (Fanapt) — A New Indication for Bipolar Disorder
- Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
- In Brief: Wezlana — An Ustekinumab Biosimilar Interchangeable with Stelara
- In Brief: Doxycycline for STI Post-Exposure Prophylaxis
- DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)
ISSUE
The FDA has approved Aurlumyn (Eicos Sciences), an IV formulation of the prostacyclin analog iloprost, to reduce the risk of digit amputation in adults with severe frostbite. Iloprost is the first drug to be approved by the FDA for treatment of severe frostbite; it has been used off-label for this indication in the EU and elsewhere for decades. In the US, iloprost is also available as an inhaled formulation (Ventavis) for treatment of pulmonary arterial hypertension.
STANDARD TREATMENT ― Frostbite occurs when freezing temperatures cause ice crystals to form in tissue. Physical examination and imaging modalities (angiography, technetium bone scan) are used to assess vascular flow to the affected area. Frostbite is classified according to severity from grade 1 (no cyanosis) to grade 4 (cyanotic injury to the metacarpal or …